TrianglePUBLICATIONS · 36054032
Low-dose dasatinib 50 mg/day versus standard-dose dasatinib 100 mg/day as frontline therapy in chronic myeloid leukemia in chronic phase: A propensity score analysis.
Open original source → · Download preserved record
Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.
- Journal
- Am J Hematol
- Publication date
- 2022 Nov
- First author
- Jabbour E
Publication notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
Authors and identifiers
- name
- Jabbour E
- type
- Author
- name
- Sasaki K
- type
- Author
- name
- Haddad FG
- type
- Author
- name
- Issa GC
- type
- Author
- name
- Skinner J
- type
- Author
- name
- Dellasala S
- type
- Author
- name
- Yilmaz M
- type
- Author
- name
- Ferrajoli A
- type
- Author
- name
- Bose P
- type
- Author
- name
- Thompson P
- type
- Author
- name
- Alvarado Y
- type
- Author
- name
- Jain N
- type
- Author
Complete bibliographic record and source provenance
- authors
- name
- Jabbour E
- type
- Author
- name
- Sasaki K
- type
- Author
- name
- Haddad FG
- type
- Author
- name
- Issa GC
- type
- Author
- name
- Skinner J
- type
- Author
- name
- Dellasala S
- type
- Author
- name
- Yilmaz M
- type
- Author
- name
- Ferrajoli A
- type
- Author
- name
- Bose P
- type
- Author
- name
- Thompson P
- type
- Author
- name
- Alvarado Y
- type
- Author
- name
- Jain N
- type
- Author
- bibliography ids
- nci-bib-d5a4cdabef2cc349a29b492b
- book metadata
- content sha256
- 01e573bb1bb7bb48e6551afd3f99dd32b9c42bba42331689231a460c261a1d91
- document type
- citation
- dois
- 10.1002/ajh.26689
- electronic publication date
- display
- 2022 Aug 27
- precision
- day
- year
- 2022
- evidence scope
- bibliographic_metadata_only
- id
- pubmed:36054032
- immutable id
- pubmed:36054032@01e573bb1bb7bb48e6551afd3f99dd32b9c42bba42331689231a460c261a1d91
- journal
- abbreviation
- Am J Hematol
- issn electronic
- 1096-8652
- issn print
- 0361-8609
- issue
- 11
- name
- American journal of hematology
- nlm unique id
- 7610369
- pages
- 1413-1418
- volume
- 97
- languages
- eng
- notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
- outcomes validated
- false
- pmid
- 36054032
- provenance
- batch id
- 9d150d55960e0c12aada
- provider
- NCBI PubMed ESummary
- record sha256
- 0661fde588295c271f551d978a905c41f2b8bf21ce6526c87a60fc2595694eab
- response sha256
- 2d4ef1cc8137eef6e7216f66bf8601c3899bc663b8626f412794d39585de6b6b
- retrieved at
- 2026-09-09T23:48:09.820498+00:00
- publication date
- display
- 2022 Nov
- precision
- month
- year
- 2022
- publication types
- Journal Article
- Research Support, Non-U.S. Gov't
- Research Support, N.I.H., Extramural
- record status
- PubMed - indexed for MEDLINE
- schema version
- 1.0
- title
- Low-dose dasatinib 50 mg/day versus standard-dose dasatinib 100 mg/day as frontline therapy in chronic myeloid leukemia in chronic phase: A propensity score analysis.
Preserved source evidence · Not medical advice